Head-to-head · free
Amphastar Pharmaceuticals, Inc. vs GSAT
AMPH vs GSAT — return on capital, cash generation, margins and balance sheet side by side.
AMPH
4 / 7
measures where AMPH leads
GSAT
3 / 7
measures where GSAT leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | AMPH · FY2025 | GSAT · FY2025 |
|---|---|---|
| Revenue | $719.9M | $273.0M |
| Net income | $98.1M | (8.7M) |
| Revenue growth (yearly, multi-year) | 13.2% | 21.7% |
| Free cash flow | $121.2M | — |
| Free cash flow margin | 16.8% | — |
| Net cash / (debt) | — | — |
| ROIC | 7.9% | — |
| Return on equity | 12.9% | -5.4% |
| Gross margin | 49.5% | 64.8% |
| Operating margin | 19.5% | 5.4% |
| Net debt / EBITDA | 2.16x | 0.38x |
Figures are as reported by each company; latest fiscal year shown.
Where Amphastar Pharmaceuticals, Inc.'s cash went (FY2025)
- Capital spending
- $34.9M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where GSAT's cash went (FY2025)
- Capital spending
- —
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free